v3.26.1
Summary of Significant Accounting Policies - Basis of Presentation and Liquidity (Details) - USD ($)
$ in Thousands
3 Months Ended
Oct. 01, 2025
Nov. 08, 2023
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Jun. 30, 2024
Dec. 31, 2023
Summary of Significant Accounting Policies              
Proceeds from sale of Orthobiologics Business     $ 425        
Incurred loss from continuing operations     7,894   $ 1,887    
Divestiture proceeds receivable     8,000 $ 8,000      
Accumulated deficit     183,682 176,213      
Cash used in operating activities     7,831   8,881    
CIED | Discontinued Operations, Disposed of by Sale              
Summary of Significant Accounting Policies              
Aggregate purchase price $ 88,000            
Proceeds from sale of Orthobiologics Business 80,400            
Inventory adjustment 400            
Indemnity holdback amount $ 8,000            
Retainment Period 12 months            
Recognized a gain       $ 76,100      
Divestiture proceeds receivable     8,000        
Divestiture of Orthobiologics | Discontinued Operations, Disposed of by Sale              
Summary of Significant Accounting Policies              
Proceeds from sale of Orthobiologics Business   $ 14,600          
Additional amount that may be earned   20,000          
Indemnity holdback amount   $ 1,500          
Retainment Period   24 months          
Earn-out payments, as a percent actual revenue   10.00%          
Earn-out period   5 years          
Earn-out payments received     0   $ 0    
Recognized a gain           $ 200 $ 6,000
Indemnity holdback amount resolved and received     $ 400